Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Itraconazole

FDA-approved product (capsule, oral), marketed as Itraconazole, Onmel, Sporanox and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Itraconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Blastomycosis
  • Candidiasis
  • Fungal infectious disease
  • Lung disease
  • Tinea
  • Tinea unguium

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC02; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Itraconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Itraconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections

    NCT00794703 · start 2008-11

    Registered record
    Registry ID
    NCT00794703
    Conditions
    Fungemia; Fungal Infections
    Interventions
    micafungin (Mycamine); itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-11
    Completion
    2009-11
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungemia; Fungal Infections
    Interventionmicafungin (Mycamine); itraconazole
    PhasePhase 3
    Registry statusCompleted

  • Study to Assess Blood Levels of Itraconazole During a Two-Week Period

    NCT00695071 · start 2008-06

    Registered record
    Registry ID
    NCT00695071
    Conditions
    Healthy
    Interventions
    Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-06
    Completion
    2008-07
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionItraconazole
    PhasePhase 1
    Registry statusCompleted

  • A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection

    NCT00784368 · start 2008-01

    Registered record
    Registry ID
    NCT00784368
    Conditions
    Mycoses; Candidiasis; Aspergillosis; Cryptococcosis; Blastomycosis; Histoplasmosis; Neutropenia
    Interventions
    ITCZ Oral Solution; ITCZ-IV
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-05
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycoses; Candidiasis; Aspergillosis; Cryptococcosis +3 more
    InterventionITCZ Oral Solution; ITCZ-IV
    PhasePhase 3
    Registry statusCompleted

  • PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

    NCT00045942 · start 2002-01-30

    Registered record
    Registry ID
    NCT00045942
    Conditions
    Acute Myeloid Leukemia; Myelodysplastic Syndromes
    Interventions
    Itraconazole; PKC412
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2002-01-30
    Completion
    2008-03-27
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Myelodysplastic Syndromes
    InterventionItraconazole; PKC412
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Assessment of Mechanisms of Improved Wound Healing

    NCT00673309 · start 2000-07

    Registered record
    Registry ID
    NCT00673309
    Conditions
    Burns
    Interventions
    Stable Isotope Infusion study; Insulin High Dose; oxandrolone; Propranolol; Growth Hormone; Insulin Low Dose; IGF-1/IGFBP-3; Itraconazole; Growth Hormone and Propranolol; Oxandrolone and Propranolol; Placebo or Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2000-07
    Completion
    2013-04
    Enrolment
    644

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns
    InterventionStable Isotope Infusion study; Insulin High Dose; oxandrolone; Propranolol +7 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted